Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Cancer Lett. 2021 Nov 20;526:53–65. doi: 10.1016/j.canlet.2021.11.018

Fig. 4. CTDSPL2 knockdown leads to impaired cell proliferation, migration, and invasion.

Fig. 4.

(A, B) Establishment of cell lines with TetOn inducible knockdown of CTDSPL2 in S2.013 (A) and PANC-1 (B) cells. (C, D) Cell proliferation assays in S2.013 (C) and PANC-1 (D) cells from A and B. ***: p=0.0002 (shRNA#A vs Control) and 7.3E-06 (shRNA#C vs Control) in panel C. ***: p=0.0003 (shRNA#A vs Control) and 2.1E-05 (shRNA#C vs Control) in panel D (Student’s t test). (E-H) Quantification of wound healing assays in established S2.013 (E) and PANC-1 (F) cells. ***: p=4.8E-05 (shRNA#A vs Control) and 9.0E-05 (shRNA#C vs Control) in panel E. ***: p=1.8E-04 (shRNA#A vs Control) and 3.2E-05 (shRNA#C vs Control) in panel F (Student’s t test). Representative images of wound healing assays in S2.013 (G) and PANC-1 (H) cells were shown. (I-N) CTDSPL2 knockdown inhibited migration and invasion in S2.013 (I, K, L) and PANC-1 (J, M, N) cells. ***: p=1.2E-05 (shRNA#A vs Control) and 6.4E-05 (shRNA#C vs Control) in panel I. ***: p=6.1E-05 (shRNA#A vs Control) and 1.1E-06 (shRNA#C vs Control) in panel J. ***: p=0.0003 (shRNA#A vs Control) and 0.0005 (shRNA#C vs Control) in panel L. ***: p=5.0E-05 (shRNA#A vs Control) and 6.6E-07 (shRNA#C vs Control) in panel M (Student’s t test). Data were expressed as the mean ± SD of three or four independent experiments.